VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 187 filers reported holding VAXCYTE INC in Q1 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,570,537 | +2.0% | 70,038 | -0.0% | 0.01% | +10.0% |
| Q2 2023 | $3,498,896 | +75.4% | 70,062 | +31.6% | 0.01% | +66.7% |
| Q1 2023 | $1,994,723 | -20.1% | 53,221 | +2.2% | 0.01% | -25.0% |
| Q4 2022 | $2,497,524 | -56.2% | 52,086 | -78.1% | 0.01% | -55.6% |
| Q3 2022 | $5,698,000 | +44.2% | 237,433 | +30.8% | 0.02% | +80.0% |
| Q2 2022 | $3,951,000 | -21.1% | 181,589 | -12.4% | 0.01% | 0.0% |
| Q1 2022 | $5,005,000 | +1.5% | 207,240 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $4,930,000 | +15.5% | 207,240 | +23.2% | 0.01% | +11.1% |
| Q3 2021 | $4,269,000 | +47.4% | 168,280 | +30.8% | 0.01% | +50.0% |
| Q2 2021 | $2,896,000 | +41.6% | 128,675 | +24.3% | 0.01% | +50.0% |
| Q1 2021 | $2,045,000 | +19.2% | 103,520 | +60.3% | 0.00% | 0.0% |
| Q4 2020 | $1,715,000 | +20.6% | 64,560 | +124.2% | 0.00% | 0.0% |
| Q3 2020 | $1,422,000 | – | 28,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $82,124,000 | 28.36% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $37,277,000 | 21.71% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,405,421 | $27,757,000 | 8.90% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $45,614,000 | 3.66% |
| RA Capital Management | 3,865,808 | $76,350,000 | 1.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 4,558,475 | $90,030,000 | 1.05% |
| Soleus Capital Management, L.P. | 293,650 | $5,800,000 | 1.04% |
| Opaleye Management Inc. | 357,800 | $7,067,000 | 1.04% |
| SABBY MANAGEMENT, LLC | 178,992 | $3,535,000 | 0.69% |
| Penn Mutual Asset Management, LLC | 22,227 | $439,000 | 0.50% |